rss
Postgrad Med J 2003;79:367-376 doi:10.1136/pmj.79.933.367
  • Review

Recombinant erythropoietin in clinical practice

  1. T Ng1,
  2. G Marx2,
  3. T Littlewood3,
  4. I Macdougall4
  1. 1Phase One Clinical Trials Unit Ltd, Plymouth, UK
  2. 2Sydney Haematology Oncology Clinic, Hornsby, New South Wales, Australia
  3. 3Department of Haematology, John Radcliff Hospital, Oxford, UK
  4. 4Department of Renal Medicine, King’s College Hospital (Dulwich), London, UK
  1. Correspondence to:
 Dr Thomas Ng, Phase One Clinical Trials Unit Ltd, 119 Looseleigh Lane, Derriford, Plymouth PL6 5HH, UK;
 tsfng{at}hotmail.com
  • Received 5 March 2002
  • Accepted 31 December 2002

Abstract

The introduction of recombinant human erythropoietin (RHuEPO) has revolutionised the treatment of patients with anaemia of chronic renal disease. Clinical studies have demonstrated that RHuEPO is also useful in various non-uraemic conditions including haematological and oncological disorders, prematurity, HIV infection, and perioperative therapies. Besides highlighting both the historical and functional aspects of RHuEPO, this review discusses the applications of RHuEPO in clinical practice and the potential problems of RHuEPO treatment.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.